However, in the osimertinib + bevacizumab group, the most frequent AEs were increased ALT/AST, hypertension, rash, or acne (with about 20% or more incidence in patients after progression on both 1st line and 2nd/3rd line of osimertinib treatment subgroups). This evidence concerns the gene GPT and acne.